Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of IVIG in combination with
Rituximab to lower the level of HLA-sensitive antibodies and block their ability to attack a
transplanted organ in patients who are highly HLA-sensitized and are awaiting
transplantation.